• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Nuvectis Pharma, Inc. - Common Stock (NQ:NVCT)

    19.84 +0.32 (+1.64%)
    Streaming Delayed Price Updated: 11:15 AM EDT, Jul 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 321,688
    Open 19.94
    Bid (Size) 19.75 (200)
    Ask (Size) 19.87 (100)
    Prev. Close 19.52
    Today's Range 19.04 - 20.35
    52wk Range 5.550 - 29.27
    Shares Outstanding 25,676,798
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Here are the top movers in Tuesday's session. ↗
    Via Chartmill
    Top movers analysis in the middle of the day on 2026-06-30: top gainers and losers in today's session. ↗
    Via Chartmill

    Performance

    YTD
    +133.1%
    +133.1%
    1 Month
    +103.5%
    +103.5%
    3 Month
    +161.1%
    +161.1%
    6 Month
    +162.8%
    +162.8%
    1 Year
    +171.4%
    +171.4%

    More News

    Read More
    Traders are paying attention to the gapping stocks in Tuesday's session. ↗
    Via Chartmill
    Tuesday's pre-market session: top gainers and losers ↗
    Via Chartmill
    Wondering what's happening in today's after-hours session? ↗
    Via Chartmill
    News headline image
    Nuvectis Pharma Announces Proposed Public Offering of Common Stock
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    Keep an eye on the top gainers and losers in Wednesday's session. ↗
    Via Chartmill
    Here are the top movers in Wednesday's session. ↗
    Via Chartmill
    News headline image
    Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis (NVCT) Q2 Loss Widens 43% ↗
    Via The Motley Fool
    News headline image
    Discover the top movers in Thursday's pre-market session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies
    From Nuvectis Pharma, Inc.
    Via GlobeNewswire
    News headline image
    Smart Money is Quietly Loading Up On This $160M Oncology Stock — Is Nuvectis Pharma the Next Breakout Biotech? (NASDAQ: NVCT)
    Via News Direct

    Frequently Asked Questions

    Is Nuvectis Pharma, Inc. - Common Stock publicly traded?
    Yes, Nuvectis Pharma, Inc. - Common Stock is publicly traded.
    What exchange does Nuvectis Pharma, Inc. - Common Stock trade on?
    Nuvectis Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Nuvectis Pharma, Inc. - Common Stock?
    The ticker symbol for Nuvectis Pharma, Inc. - Common Stock is NVCT on the Nasdaq Stock Market
    What is the current price of Nuvectis Pharma, Inc. - Common Stock?
    The current price of Nuvectis Pharma, Inc. - Common Stock is 19.84
    When was Nuvectis Pharma, Inc. - Common Stock last traded?
    The last trade of Nuvectis Pharma, Inc. - Common Stock was at 07/02/26 11:15 AM ET
    What is the market capitalization of Nuvectis Pharma, Inc. - Common Stock?
    The market capitalization of Nuvectis Pharma, Inc. - Common Stock is 509.43M
    How many shares of Nuvectis Pharma, Inc. - Common Stock are outstanding?
    Nuvectis Pharma, Inc. - Common Stock has 509M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.